Dr. Joseph Weinstock
10 Painters Lane
Wayne, PA 19087-5504
Phone:
(610) 725-8054
E-mail: jweinstock@earthlink.net
Specialties:
- Pharmaceutical
- Organic Chemistry
- Synthesis
- Medicinal Chemistry
- Patents
Services:
Forty-five years of successful application of medicinal chemistry to the design and synthesis of drugs.
Expertise in the evaluation of compounds as hits in screens, leads for medicinal chemistry synthesis, and as development candidates.
Abilities documented by three marketed drugs, over 140 publications and over 110 U.S. patents as well as numerous non-US patents and patent applications.
Active as a consultant and expert witness in patent litigation.
Brief Resume:
Forty-five years of successful application of medicinal chemistry to the design and synthesis of drugs. Expertise in the evaluation of compounds as hits in screens, leads for medicinal chemistry synthesis, and as development candidates. Abilities documented by three marketed drugs, over 140 publications and over 100 U.S. issued patents as well as numerous non-US patents and patent applications. Consultant in pharmaceutical patent litigation and medicinal chemistry research.
Retired Director, Medicinal Chemistry Department, GlaxoSmithKline
Professional Chronology:
- B.S. in Chemistry, Rutgers University, 1949.
- Ph.D., Organic Chemistry, University of Rochester, 1952.
- Postdoctoral Fellow, Chemistry Department, Northwestern University, 1952-1954.
- Instructor, Chemistry Department, Northwestern University, 1954-1956.
- Consultant, Evanston Hospital Cholesterol Research Group, 1952-1956.
- Senior Medicinal Chemist, SK&F - Director, Medicinal Chemistry, GSK, 1956-2002.
- Consultant, 2002-present.
Consulting Experience:
- Consultant for research groups in big pharma and start-ups.
- Consultant and expert witness for major law firms litigating patents on blockbuster drugs.
Major Research Contributions - SmithKline:
- Originator and Director of the Angiotensin II Antagonist Program - *Eprosartan (Tevetan)* is a marketed product.
- Director and Principal Chemist for Renal Vasodilator Program -*Fenoldopam (Corlopam)* is a marketed product.
- Principal Chemist for team which discovered the SB major products *Dyazide *and* Dyrenium*. Key role in chemistry of additional compounds which were studied in the clinic for diuretic, hypotensive, and anti-inflammatory activity.
- Made substantial contributions to the chemistry of benzazepines, vulpinic acids, gold complexes, endothelin antagonists, NK3 antagonists, antibiotics, heterocycles, and combinatorial and array chemistry.
- Worked in the areas of diuretics, antihypertensives, dopaminergics, metalloprotease inhibitors, atherosclerosis inhibitors, and phosphate transport inhibitors for renal failure and uremic bone disease.
- Established and directed a Drug Metabolism - Medicinal Chemistry Laboratory.
- Have been author or co-author of many publications and U.S. patents plus numerous foreign patents - *over 110 issued U.S. Patents and over 140 publications and meeting presentions. *
Major Research Interests - Pre SmithKline:
- Graduate Work: Developed the alkylation and discovered the rearrangement of Reissert compounds. Elucidated the structure of the alkaloid beta-erythroidine by degradation. Developed a much improved Hofmann elinination reaction.
- Post-doctoral Research: stereochemistry, regiochemistry, and mechanism of elimination reactions, synthesis and reactions of sulfur heterocycles.
- Academic Research: reaction mechanisms: elimination reactions, free radical reactions, pyrolytic reactions.
